{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:55:08Z","timestamp":1781513708673,"version":"3.54.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05166-3","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:34:04Z","timestamp":1773196444000},"page":"12401-12418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global research trends and hotspots in targeted therapy for IgA nephropathy: a bibliometric and visualization analysis (1999\u20132025)"],"prefix":"10.1007","volume":"399","author":[{"given":"Cunhong","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"5166_CR1","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.2147\/DDDT.S383138","volume":"18","author":"J Barratt","year":"2024","unstructured":"Barratt J, Kristensen J, Pedersen C et al (2024) Insights on Nefecon, a targeted release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy. Drug Des Devel Ther 18:3679\u20133689. https:\/\/doi.org\/10.2147\/DDDT.S383138","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"5166_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.10.018","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J et al (2023b) Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 103(2):391\u2013402. https:\/\/doi.org\/10.1016\/j.kint.2022.10.018","journal-title":"Kidney Int"},{"issue":"2","key":"5166_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","volume":"104","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette RA, Zhang H, Tesar V, Rovin BH, Tumlin JA et al (2023) IgA nephropathy: the lectin pathway and implications for targeted therapy. Kidney Int 104(2):254\u2013264. https:\/\/doi.org\/10.1016\/j.kint.2023.04.029","journal-title":"Kidney Int"},{"issue":"10","key":"5166_CR4","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ekir.2022.07.016","volume":"7","author":"J Barratt","year":"2022","unstructured":"Barratt J, Rovin BH, Cattran D et al (2022) Why target the gut for the treatment of IgA nephropathy? Kidney Int Rep 7(10):2309\u20132319. https:\/\/doi.org\/10.1016\/j.ekir.2022.07.016","journal-title":"Kidney Int Rep"},{"key":"5166_CR5","doi-asserted-by":"publisher","unstructured":"Berthoux F, Suzuki H, Thibaudin L et al (2011) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 22(4):752\u2013761. https:\/\/doi.org\/10.1681\/ASN.2010040355","DOI":"10.1681\/ASN.2010040355"},{"issue":"21","key":"5166_CR6","doi-asserted-by":"publisher","first-page":"12949","DOI":"10.3390\/ijms232112949","volume":"23","author":"MM Bishop","year":"2022","unstructured":"Bishop MM, Brown TM, Zhang J et al (2022) Emerging immunomodulatory targets for IgA nephropathy therapy. Int J Mol Sci 23(21):12949. https:\/\/doi.org\/10.3390\/ijms232112949","journal-title":"Int J Mol Sci"},{"key":"5166_CR7","doi-asserted-by":"publisher","unstructured":"Cattran DC, Coppo R, Cook HT et al (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 76(5):534\u2013545. https:\/\/doi.org\/10.1038\/ki.2009.243","DOI":"10.1038\/ki.2009.243"},{"key":"5166_CR8","unstructured":"Calliditas Therapeutics (2023) Calliditas announces positive results from Phase 3 NefIgArd trial of Nefecon in IgA nephropathy [press release]. Available at:\u00a0https:\/\/www.calliditas.se\/en\/"},{"issue":"2","key":"5166_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/j.ajkd.2023.09.006","volume":"83","author":"DJ Caster","year":"2024","unstructured":"Caster DJ, Lafayette RA (2024) The treatment of primary IgA nephropathy: change, change, change. Am J Kidney Dis 83(2):229\u2013240. https:\/\/doi.org\/10.1053\/j.ajkd.2023.09.006","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"5166_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","volume":"57","author":"CM Chen","year":"2006","unstructured":"Chen CM (2006) CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol 57(3):359\u2013377. https:\/\/doi.org\/10.1002\/asi.20317","journal-title":"J Am Soc Inf Sci Technol"},{"key":"5166_CR11","doi-asserted-by":"publisher","unstructured":"Cheung CK, Barratt J (2025) The rapidly changing treatment landscape of IgA nephropathy. Semin Nephrol 44(5). [published online ahead of print, 2025 Jul 4]. https:\/\/doi.org\/10.1016\/j.semnephrol.2025.05.004","DOI":"10.1016\/j.semnephrol.2025.05.004"},{"issue":"9","key":"5166_CR12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/ndt\/gfac296","volume":"38","author":"CK Cheung","year":"2023","unstructured":"Cheung CK, Dormer JP, Barratt J (2023) The role of complement in glomerulonephritis \u2013 are novel therapies ready for prime time? Nephrol Dial Transplant 38(9):1789\u20131797. https:\/\/doi.org\/10.1093\/ndt\/gfac296","journal-title":"Nephrol Dial Transplant"},{"key":"5166_CR13","doi-asserted-by":"publisher","unstructured":"Coppo R, Peruzzi L, Amore A et al (2007) IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. Journal of the American Society of Nephrology (JASN) 18(6):1880. https:\/\/doi.org\/10.1681\/ASN.2006040347","DOI":"10.1681\/ASN.2006040347"},{"key":"5166_CR14","doi-asserted-by":"publisher","unstructured":"Coppo R, Troyanov S, Bellur S et al (2014) Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. https:\/\/doi.org\/10.1038\/ki.2014.63","DOI":"10.1038\/ki.2014.63"},{"issue":"6","key":"5166_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099006","volume":"9","author":"M De Angelis","year":"2014","unstructured":"De Angelis M, Montemurno E, Piccolo M et al (2014) Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 9(6):e99006. https:\/\/doi.org\/10.1371\/journal.pone.0099006","journal-title":"PLoS One"},{"key":"5166_CR16","doi-asserted-by":"publisher","unstructured":"Eckardt KU, Kellum JA, Lameire N, Levin A (2012) KDIGO clinical practice guideline for acute kidney injury: foreword. Kidney Int Suppl 2(1):7. https:\/\/doi.org\/10.1038\/kisup.2012.8","DOI":"10.1038\/kisup.2012.8"},{"issue":"10084","key":"5166_CR17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H et al (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN trial): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 389(10084):2117\u20132127. https:\/\/doi.org\/10.1016\/S0140-6736(17)30550-0","journal-title":"Lancet"},{"key":"5166_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1436923","volume":"15","author":"EJ Filippone","year":"2024","unstructured":"Filippone EJ, Gulati R, Farber JL (2024) Contemporary review of IgA nephropathy. Front Immunol 15:1436923. https:\/\/doi.org\/10.3389\/fimmu.2024.1436923","journal-title":"Front Immunol"},{"issue":"5","key":"5166_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2022.07.012","volume":"102","author":"J Floege","year":"2022","unstructured":"Floege J, Barbour SJ, Cattran DC et al (2022) Management and treatment of IgA nephropathy: a contemporary update. Kidney Int 102(5):983\u2013999. https:\/\/doi.org\/10.1016\/j.kint.2022.07.012","journal-title":"Kidney Int"},{"issue":"4","key":"5166_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Bernier Jean A, Barratt J et al (2025) Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int 107(4):640\u2013651. https:\/\/doi.org\/10.1016\/j.kint.2025.01.014","journal-title":"Kidney Int"},{"issue":"1","key":"5166_CR21","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1080\/10717544.2020.1820093","volume":"27","author":"Q Guo","year":"2020","unstructured":"Guo Q, Lu X, Gao Y et al (2020) Advances in targeted drug delivery systems for kidney diseases. Drug Deliv 27(1):1474\u20131485. https:\/\/doi.org\/10.1080\/10717544.2020.1820093","journal-title":"Drug Deliv"},{"issue":"10371","key":"5166_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0140-6736(22)02590-9","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Perkovic V, Hogan JJ et al (2023) Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 401(10371):101\u2013110. https:\/\/doi.org\/10.1016\/S0140-6736(22)02590-9","journal-title":"Lancet"},{"issue":"6","key":"5166_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine MJ, Kohan DE et al (2025) Atrasentan in patients with IgA nephropathy. N Engl J Med 392(6):524\u2013534. https:\/\/doi.org\/10.1056\/NEJMoa2409415","journal-title":"N Engl J Med"},{"issue":"49","key":"5166_CR24","doi-asserted-by":"publisher","first-page":"19193","DOI":"10.1073\/pnas.0707962104","volume":"104","author":"JE Hirsch","year":"2007","unstructured":"Hirsch JE (2007) Does the h index have predictive power? Proc Natl Acad Sci USA 104(49):19193\u201319198. https:\/\/doi.org\/10.1073\/pnas.0707962104","journal-title":"Proc Natl Acad Sci USA"},{"key":"5166_CR25","doi-asserted-by":"publisher","unstructured":"Hossain SKA, Islam MN, Ahmed AHH et al (2026) Predicting the course of immunoglobulin A nephropathy using urinary soluble cluster of differentiation 163 as a prognostic biomarker [J]. Cureus.\u00a0https:\/\/doi.org\/10.7759\/cureus.101499","DOI":"10.7759\/cureus.101499"},{"key":"5166_CR26","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1097\/JS9.0000000000000492","volume":"109","author":"S Jiang","year":"2023","unstructured":"Jiang S et al (2023) Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis. Int J Surg 109:2774\u20132783. https:\/\/doi.org\/10.1097\/JS9.0000000000000492","journal-title":"Int J Surg"},{"issue":"4S","key":"5166_CR27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1-276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"11","key":"5166_CR28","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","volume":"46","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46(11):1187\u20131196. https:\/\/doi.org\/10.1038\/ng.3118","journal-title":"Nat Genet"},{"key":"5166_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599974","volume":"11","author":"JJE Koopman","year":"2021","unstructured":"Koopman JJE, van Essen MF, Rennke HG et al (2021) Deposition of the membrane attack complex in healthy and diseased human kidneys. Front Immunol 11:599974. https:\/\/doi.org\/10.3389\/fimmu.2020.599974","journal-title":"Front Immunol"},{"key":"5166_CR30","doi-asserted-by":"publisher","unstructured":"Lafayette RA, Canetta PA, Rovin BH et al (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. Journal of the American Society of Nephrology: JASN 28(4):1306\u20131313. https:\/\/doi.org\/10.1681\/ASN.2016060640","DOI":"10.1681\/ASN.2016060640"},{"key":"5166_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.1","volume":"2","author":"KN Lai","year":"2016","unstructured":"Lai KN, Tang SCW, Schena FP et al (2016) IgA nephropathy. Nat Rev Dis Primers 2:16001. https:\/\/doi.org\/10.1038\/nrdp.2016.1","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"5166_CR32","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/j.ekir.2024.07.031","volume":"9","author":"J Li","year":"2024","unstructured":"Li J, Lv J, Wong MG et al (2024) Correlation of urinary soluble CD163 levels with disease activity and treatment response in IgA nephropathy. Kidney Int Rep 9(10):3016\u20133026. https:\/\/doi.org\/10.1016\/j.ekir.2024.07.031","journal-title":"Kidney Int Rep"},{"key":"5166_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.729993","volume":"8","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li H, Zuo K et al (2021) Bibliometric analysis of global research on IgA nephropathy: 2000\u20132020. Front Med (Lausanne) 8:729993. https:\/\/doi.org\/10.3389\/fmed.2021.729993","journal-title":"Front Med (Lausanne)"},{"key":"5166_CR34","doi-asserted-by":"publisher","unstructured":"Lv J, Xu D, Perkovic V et al (2012) Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 23(6):1108\u20131116. https:\/\/doi.org\/10.1681\/ASN.2011111112","DOI":"10.1681\/ASN.2011111112"},{"key":"5166_CR35","doi-asserted-by":"publisher","unstructured":"Lv J, Wong MG, Hladunewich MA et al (2022) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 327(19):1888\u20131898. https:\/\/doi.org\/10.1001\/jama.2022.5368","DOI":"10.1001\/jama.2022.5368"},{"issue":"11","key":"5166_CR36","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/ndt\/gfz228","volume":"35","author":"EP McQuarrie","year":"2020","unstructured":"McQuarrie EP, Mackinnon B, Young B et al (2020) Utility of long-term renal registries in glomerular disease: insights from Scottish Renal Biopsy Registry. Nephrol Dial Transplant 35(11):1905\u20131914. https:\/\/doi.org\/10.1093\/ndt\/gfz228","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"5166_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00281-021-00873-w","volume":"43","author":"NR Medjeral\u2011Thomas","year":"2021","unstructured":"Medjeral\u2011Thomas NR, Cook HT (2021) Complement activation in IgA nephropathy. Semin Immunopathol 43(5):679\u2013690. https:\/\/doi.org\/10.1007\/s00281-021-00873-w","journal-title":"Semin Immunopathol"},{"key":"5166_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102593","volume":"118","author":"Z Moldoveanu","year":"2021","unstructured":"Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N et al (2021) Experimental evidence of pathogenic role of IgG auto antibodies in IgA nephropathy. J Autoimmun 118:102593. https:\/\/doi.org\/10.1016\/j.jaut.2021.102593","journal-title":"J Autoimmun"},{"issue":"3","key":"5166_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091756","volume":"9","author":"T Moriyama","year":"2014","unstructured":"Moriyama T, Tanaka K, Iwasaki C et al (2014) Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One 9(3):e91756. https:\/\/doi.org\/10.1371\/journal.pone.0091756","journal-title":"PLoS One"},{"key":"5166_CR40","unstructured":"Novartis (2024) Novartis receives FDA accelerated approval for Fabhalta\u00ae (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN). Available at: https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan. Accessed 6 Mar 2026"},{"issue":"4","key":"5166_CR41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ndt\/gfx189","volume":"33","author":"MM O'Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC (2018) Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transplant 33(4):661\u2013669. https:\/\/doi.org\/10.1093\/ndt\/gfx189","journal-title":"Nephrol Dial Transplant"},{"key":"5166_CR42","unstructured":"Omeros (2023) Announces Update on Phase 3 ARTEMIS-IGAN Trial. Available at https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-announces-update-phase-3-artemis-igan-trial. Accessed 6 Mar 2026"},{"key":"5166_CR43","doi-asserted-by":"publisher","unstructured":"Patel U, Floege J, Barratt J et al (2025) FELZARTAMAB for IgA nephropathy: final results of the IGNAZ study. Kidney Int Rep 10(2). [published online ahead of print, 2025 Jul 4]. https:\/\/doi.org\/10.1016\/j.ekir.2025.06.007.","DOI":"10.1016\/j.ekir.2025.06.007"},{"issue":"6","key":"5166_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B et al (2025) Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med 392(6):513\u2013523. https:\/\/doi.org\/10.1056\/NEJMoa2410316","journal-title":"N Engl J Med"},{"issue":"6","key":"5166_CR45","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA et al (2023) Long term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18(6):727\u2013738. https:\/\/doi.org\/10.2215\/CJN.0000000000000135","journal-title":"Clin J Am Soc Nephrol"},{"key":"5166_CR46","doi-asserted-by":"publisher","unstructured":"Pozzi C (1999) Corticosteroids in IgA nephropathy: a randomized controlled trial. Lancet 353(9156):883\u2013887. https:\/\/doi.org\/10.1016\/S0140-6736(98)03563-6","DOI":"10.1016\/S0140-6736(98)03563-6"},{"issue":"1","key":"5166_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08764.7C","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L et al (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15(1):157\u2013163. https:\/\/doi.org\/10.1097\/01.ASN.0000103869.08764.7C","journal-title":"J Am Soc Nephrol"},{"key":"5166_CR48","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1415463","journal-title":"N Engl J Med"},{"issue":"4","key":"5166_CR49","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4):753\u2013779. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015","journal-title":"Kidney Int"},{"key":"5166_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104608.","volume":"136","author":"M Sabe","year":"2022","unstructured":"Sabe M, Pillinger T, Kaiser S et al (2022) Half a century of research on antipsychotics and schizophrenia: a scientometric study of hotspots, nodes, bursts, and trends. Neurosci Biobehav Rev 136:104608. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104608.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"5166_CR51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I (2018) Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol 38(5):435\u2013442. https:\/\/doi.org\/10.1016\/j.semnephrol.2018.05.013","journal-title":"Semin Nephrol"},{"issue":"4","key":"5166_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122743","volume":"10","author":"H Suzuki","year":"2015","unstructured":"Suzuki H, Fan R, Zhang Z et al (2015) IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. PLoS ONE 10(4):e0122743. https:\/\/doi.org\/10.1371\/journal.pone.0122743","journal-title":"PLoS ONE"},{"issue":"10","key":"5166_CR53","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22(10):1795\u20131803. https:\/\/doi.org\/10.1681\/ASN.2011050464","journal-title":"J Am Soc Nephrol"},{"key":"5166_CR54","doi-asserted-by":"publisher","unstructured":"Suzuki H, Yasutake J, Makita Y et al (2018) IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int 93(3). https:\/\/doi.org\/10.1016\/j.kint.2017.10.019","DOI":"10.1016\/j.kint.2017.10.019"},{"issue":"5","key":"5166_CR55","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC et al (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 91(5):1014\u20131025. https:\/\/doi.org\/10.1016\/j.kint.2017.02.003","journal-title":"Kidney Int"},{"key":"5166_CR56","unstructured":"Vera Therapeutics Inc (2024) Vera Therapeutics Presents Positive 72-Week Data Showinge GFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy. Available at:\u00a0https:\/\/www.globenewswire.com\/news-release\/2024\/01\/25\/2816523\/0\/en\/Vera-Therapeutics-Presents-Positive-72-Week-Data-Showing-eGFR-Stabilization-in-the-Phase-2b-ORIGIN-Clinical-Trial-OLE-in-IgA-Nephropathy.html. Accessed 6 Mar 2026"},{"issue":"11","key":"5166_CR57","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/ndt\/gfac024","volume":"37","author":"Z Wang","year":"2022","unstructured":"Wang Z, Jiang Y, Chen P et al (2022) The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: a cohort study. Nephrol Dial Transplant 37(11):2119\u20132127. https:\/\/doi.org\/10.1093\/ndt\/gfac024","journal-title":"Nephrol Dial Transplant"},{"key":"5166_CR58","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12882-023-03246-8","volume":"24","author":"T Wu","year":"2023","unstructured":"Wu T, Ding X, Gao Y et al (2023) Global trends and prospects in IgA nephropathy research: a bibliometric analysis. BMC Nephrol 24:232. https:\/\/doi.org\/10.1186\/s12882-023-03246-8","journal-title":"BMC Nephrol"},{"issue":"3","key":"5166_CR59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/cei.12128","volume":"173","author":"G Xin","year":"2013","unstructured":"Xin G, Shi W, Xu LX, Li KS, Guo YL, Wang NS (2013) Serum BAFF levels increase in patients with IgA nephropathy and may be associated with disease activity. Clin Exp Immunol 173(3):413\u2013420. https:\/\/doi.org\/10.1111\/cei.12128","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"5166_CR60","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.18520\/cs\/v116\/i11\/1909-1914","volume":"116","author":"AWK Yeung","year":"2019","unstructured":"Yeung AWK (2019) Comparison between Scopus, Web of Science, PubMed and publishers for mislabelled review papers. Curr Sci 116(11):1909\u20131914. https:\/\/doi.org\/10.18520\/cs\/v116\/i11\/1909-1914","journal-title":"Curr Sci"},{"key":"5166_CR61","doi-asserted-by":"publisher","unstructured":"Yoshikawa N (2006) Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1(3):511\u2013517. https:\/\/doi.org\/10.2215\/CJN.01120905","DOI":"10.2215\/CJN.01120905"},{"issue":"2","key":"5166_CR62","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-3083.2009.02234.x.","volume":"70","author":"JJ Zhang","year":"2009","unstructured":"Zhang JJ, Jiang L, Liu G et al (2009) Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity. Scand J Immunol 70(2):142\u2013147. https:\/\/doi.org\/10.1111\/j.1365-3083.2009.02234.x.","journal-title":"Scand J Immunol"},{"key":"5166_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1509-5.","volume":"20","author":"M Zhang","year":"2019","unstructured":"Zhang M, Huang J, Zhang Y et al (2019) Complement activation products in the circulation and urine of primary membranous nephropathy. BMC Nephrol 20:313. https:\/\/doi.org\/10.1186\/s12882-019-1509-5.","journal-title":"BMC Nephrol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05166-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:19:37Z","timestamp":1781511577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05166-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5166"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05166-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statament of Ethics"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Employment"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Non-Financial interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Clinical trial number"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}